Last update 21 Nov 2024

APX3330

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
Target
Mechanism
APE1 inhibitors(DNA-(apurinic or apyrimidinic site) lyase inhibitors)
Originator Organization
Inactive Organization-
Drug Highest PhasePhase 2
First Approval Date-
Regulation-
Login to view timeline

Structure

Molecular FormulaC21H30O6
InChIKeyAALSSIXXBDPENJ-FYWRMAATSA-N
CAS Registry136164-66-4

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Advanced Malignant Solid NeoplasmNDA/BLA
US
30 Jan 2018
Hematologic DiseasesNDA/BLA--
Liver DiseasesNDA/BLA--
Inflammatory Bowel DiseasesPhase 2
US
07 Jun 2023
Macular EdemaPhase 2
US
30 Jan 2022
Diabetic macular oedemaPhase 2
US
08 Apr 2021
Nonproliferative diabetic retinopathyPhase 2
US
08 Apr 2021
Proliferative retinopathy with diabetes mellitusPhase 2
US
08 Apr 2021
Peripheral Nervous System DiseasesPhase 1--
Dystrophy, MacularPreclinical--
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Biospace
ManualManual
Phase 2
-
(hhshqfecbr) = A higher percentage of placebo-treated patients had ≥ 3-step worsening on binocular DRSS from baseline compared to APX3330-treated patients at 24 weeks. bksucbqbuv (xqkqhpkiyd )
Positive
02 Nov 2023
Not Applicable
-
nkjflbqkdr(bfllqxdjsi) = Incidence of pruritus and rash was higher in APX-treated subjects. These events were predominantly mild and occurred sporadically during treatment period and resolved despite continued treatment without dose de-escalation. No subjects withdrew due to rash or pruritis. zhgoluyqag (ctckyhulwt )
-
05 Oct 2023
Placebo
Not Applicable
103
(wsboxzvkhr) = AEs that occurred in ≥5% of subjects were pruritis, rash, and worsening of DR or DME in the placebo group lxziawnfvj (tuwtugdidi )
Positive
20 Jun 2023
Placebo
Phase 2
103
(tfzczpgwfx) = ulhektpzgo myrmjpjbda (afrahrrppp )
-
01 Jun 2023
Placebo
(tfzczpgwfx) = hcpbfuccmt myrmjpjbda (afrahrrppp )
Phase 1
19
zhklmmchag(vovyolpwcg) = sldgqaegea pfhjlqlpet (elrslhuadz )
-
26 May 2019
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free